Literature DB >> 6175810

Pharmacokinetics of amiodarone in man.

E Riva, M Gerna, R Latini, P Giani, A Volpi, A Maggioni.   

Abstract

We studied the kinetics of amiodarone in three healthy volunteers after single oral (400 mg) and intravenous (150 mg) doses and in six patients with supraventricular tachycardia. Three patients were studied after the first oral dose (400 mg) and during subsequent therapy (200 mg/day); the other three after 5 mg/kg of amiodarone intravenous. Blood was drawn at intervals for 24 h in patients and up to 32 h (i.v.) and 50 h (p.o.) from healthy volunteers. The drug was measured by high pressure liquid chromatography (HPLC). No difference in kinetic parameters was found between healthy subjects an patients. The pharmacokinetic parameters, calculated on the intravenous data using a two-compartment open model, indicate a very large volume of distribution (9.26-17.17 L/kg in healthy volunteers and 6.88-21.05 L/kg in patients). The elimination half-life ranged from 12.09 to 20.70 h in volunteers and from 11.60 to 19.60 h in patients. Oral absorption was slow an erratic, with fourfold individual variations in systemic bioavailability (22-86%). A slight accumulation of amiodarone was observed in patients under chronic treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175810     DOI: 10.1097/00005344-198203000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

Review 1.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

2.  In vitro amiodarone protein binding and its interaction with warfarin.

Authors:  P Neyroz; M Bonati
Journal:  Experientia       Date:  1985-03-15

3.  Bioavailability of drugs with long elimination half-lives.

Authors:  R Urso; L Aarons
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

6.  Side effects with amiodarone therapy.

Authors:  R Shukla; N I Jowett; D R Thompson; J E Pohl
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

Review 7.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

8.  Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats.

Authors:  S J Weir; C T Ueda
Journal:  J Pharmacokinet Biopharm       Date:  1986-12

9.  Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers.

Authors:  E Riva; L Aarons; R Latini; P Neyroz; R Urso
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Plasma amiodarone concentrations during intravenous infusion.

Authors:  A H Watt; A Hutchings; M R Stephens; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.